Founded in 2019 and headquartered in La Jolla, California, Iambic Therapeutics is a biotech with a unique AI-driven drug-discovery platform that delivers high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action in cancer and other disease areas. Led by CEO Dr. Tom Miller, Iambic raised a $100m Series B round in September 2023, co-led by Ascenta and Abingworth. Iambic also announced concurrently that NVIDIA (NASDAQ: NVDA) made an equity investment and started a partnership with Iambic.